Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorYork University

About this trial

Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-weeks of taurine supplementation (self-administered), on vascular function and the cardio/cerebrovascular responses to upright posture. We will measure resting vascular function with an EndoPAT device, resting heart rate variability, and the blood pressure, heart rate, and brain blood flow responses to 5 minutes of head-up tilt before and after weeks of taurine supplementation in LC. We hypothesize that the 12 weeks of supplementation will improve both resting vascular function and the responses to upright tilt. In turn, we hypothesize that symptoms will also improve (as measured by questionnaires).

Eligibility criteria

Qualifiers

Participants will have had symptoms of Long COVID post-infection for at least 3 months

Disqualifiers

Inability to undergo tilt table testing for 5 minutes

Inability to transport selves to York University from their homes

Inability to speak English, or provide a translator

Blood clotting disorders

Trial design

Treatments tested in this trial

  • Taurine supplementation

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators

York University

Lead sponsor

Canadian Institutes of Health Research (CIHR)

Collaborator